The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to find out which of these treatments best prevents death, heart attack (also called myocardial infarction) or stroke during the first year after the heart event while also keeping serious bleeding low. Participants will take the assigned tablet once daily for up to 12 months and will attend scheduled visits to monitor their health.

During the year, participants will have regular visits where doctors check health, ask about any new problems, and record any occurrences of heart attack, stroke, death, or major bleeding. This information is used to compare the safety and effectiveness of the medicines.

The purpose of the study is to assess how safe the new injection is and how it changes the activity of a clotting protein called factor XI (FXI) over a 16‑week period. Participants will be randomly assigned to receive one of two hidden doses of the injection or the placebo, and all will receive the open‑label tablet. Visits will include simple blood draws to measure FXI activity and routine safety checks such as checking for bleeding or other side effects.

Throughout the trial, researchers will watch for any bleeding events, record any adverse experiences, and perform standard laboratory tests and vital‑sign measurements. Blood samples will also be taken at several time points to see how the drug behaves in the body and whether the immune system produces any antibodies against it.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

Participants are assigned to one of the study treatments and receive injections over time during regular study visits. The study team follows how the cancer responds and watches for side effects and other health changes. It also looks at how long the treatment effects last and how the treatments affect daily well-being and symptoms.

Children are randomly assigned to receive either the study drug or the placebo during the operation. The anesthesia team uses heart rate variability and electroencephalography to guide how deep the anesthesia is. After surgery, the child’s behavior is checked at 15, 30 and 45 minutes after waking using the PAEDs score and simple pain scales to see if delirium or pain is present. The length of stay in the recovery area and any side effects are also recorded.

Participants in the study will receive either duvakitug or a placebo through a subcutaneous injection, which is a shot administered just under the skin. This is a randomized study, meaning participants are assigned to a group by chance, and it is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The study involves monitoring the condition over a period of time to observe how the body responds to the medication.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

The study is divided into different parts. People who join this particular part of the study will be those who have already shown improvement after earlier treatment and have completed certain examinations. The study will look at whether Duvakitug can help keep the condition in a state where symptoms are minimal or absent, which is called remission. During the study, doctors will check the condition of the intestine using an examination that looks inside the bowel, and they will also assess symptoms such as bowel movements, bleeding, and abdominal pain. The study will also look at whether people can stop using steroid medications while maintaining good control of their condition.

Throughout the study, participants will be monitored for any side effects or unwanted reactions to the treatment. The study will measure various aspects of the disease and how it affects daily life, including fatigue levels, quality of life, and the need for hospital care related to ulcerative colitis. Blood samples will be taken to measure the amount of Duvakitug in the body and to check if the body develops any immune response to the medication. The study will also include a longer extension period for people who complete the main part of the study, allowing for continued observation of the medication’s effects and safety over time.

The purpose of this study is to assess how well Duvakitug works as an initial treatment for moderately to severely active Ulcerative Colitis compared to placebo. The study will look at whether the medication can help reduce symptoms and inflammation in the intestines. This is called an induction study, which means it focuses on the first phase of treatment to see if the medication can bring the disease under control.

The study will measure several outcomes to determine if the treatment is working. The main outcome will be the proportion of participants who achieve clinical remission, which means their symptoms have improved significantly or disappeared. Other outcomes include improvements in the appearance of the intestine lining as seen during examination, reduction in symptoms like bowel urgency and abdominal pain, improvements in quality of life, and whether participants need to be hospitalized due to their condition. The study will also monitor any side effects and measure the levels of the medication in the blood over time. The treatment period will last up to 24 weeks.

The purpose of this study is to evaluate the safety and tolerability of MK-3120 when used alone as a treatment. The study will look at how well people can handle the treatment and what side effects might occur. The study is divided into phases, with the first phase focusing on finding the right dose and understanding safety, while the second phase will look more closely at how well the treatment works. People taking part in this study will either have never received a treatment called BCG (Bacillus Calmette-Guérin), which is a common bladder cancer treatment, or they will have received BCG in the past but their cancer has returned. The study will track whether participants experience dose-limiting toxicity, which means side effects serious enough to require stopping or reducing the treatment dose, and will count how many people have adverse events or need to stop treatment because of side effects.

During the study, participants will receive MK-3120 directly into their bladder at scheduled times. The study will also measure the complete response rate, which means how many people have their cancer completely disappear after treatment. Before joining the study, participants must have had a procedure called transurethral resection of bladder tumor, which is a surgery to remove bladder tumors through the urethra, performed within a certain timeframe. The study will continue for several years to follow participants and gather information about the long-term effects of the treatment.

During the study, participants will receive treatment for up to 12 months. The researchers will measure several things to see if the treatment is helping, including changes in body weight and appetite over a 12-week period. Body weight will be tracked from the beginning of the study, and appetite will be measured using a questionnaire that asks specific questions about eating and food-related concerns. The study will also look at muscle mass using imaging scans such as CT or MRI, which are types of medical imaging that create detailed pictures of the inside of the body. Physical function will be tested through simple exercises like a chair stand test, and daily physical activity levels will be monitored.

Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. Participants will also complete questionnaires about their quality of life, how severe their symptoms are, and whether they notice any changes in their condition. Blood samples will be taken to measure the levels of the medication in the body. The study will track overall health outcomes and how the cancer responds to ongoing treatment during this time.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

The purpose of this study is to examine how well long-term maintenance treatment with ketamine works for keeping depression symptoms from coming back after an initial treatment period. The study is designed to compare different treatment approaches over time to see which one is most effective at preventing depression from returning. Participants will be divided into three different treatment groups to compare the results. The study will look at how long it takes for depression symptoms to come back after the initial treatment phase and after the last ketamine infusion, using a depression rating scale to measure symptom severity.

During the study, participants will receive ketamine infusions according to their assigned treatment group, with the treatment lasting up to 10 days in total. The maximum daily dose will be 150 milligrams, and the maximum total dose across all infusions will be 2700 milligrams. Throughout the study, doctors will monitor participants for any unwanted effects or reactions to the treatment through interviews, observations, questionnaires, and review of medical records. Women who could become pregnant must have a negative pregnancy test before starting the study and before each maintenance ketamine infusion, and must use highly effective birth control methods throughout their participation in the study.

The purpose of this study is to evaluate the long-term safety and how well mezagitamab works in adults who have already participated in previous studies with this medicine and completed those studies. The study will look at whether the treatment causes any unwanted effects over a longer period of time and whether it continues to help maintain platelet counts at safe levels. The study will also examine how long the positive effects on platelet counts last, whether people need fewer other medicines for their condition, and whether they need less emergency treatment for low platelet counts.

During the study, participants will receive mezagitamab through subcutaneous injection, which means the medicine is injected into the tissue just under the skin. The treatment can continue for up to 104 weeks. Throughout the study, doctors will monitor participants for any side effects and measure how the body responds to the treatment by checking platelet counts and other blood tests. The study will also check how the medicine moves through the body and whether the body develops any reaction against the medicine over time.

The purpose of the study is to find out if Mezagitamab can help increase the number of platelets in the blood and keep them at a safe level over time in adults with this condition. The study will also look at whether the medicine is safe and how well it works compared to placebo. People taking part may continue some of their current treatments for this condition during the study if their doctor thinks it is appropriate. These might include medicines that help the body make more platelets or certain steroid medicines.

During the study, participants will receive injections of either Mezagitamab or placebo for up to 24 months. Regular blood tests will be done to measure platelet levels, and doctors will check for any bleeding problems or side effects. The study will measure how many people achieve and maintain a platelet count that is considered safe, which is at least 50,000 platelets per microliter of blood. Participants will also be asked about their symptoms and quality of life throughout the study.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The treatment plan involves giving medications before surgery (neoadjuvant therapy) to shrink the tumor. The study medications are given through an intravenous infusion directly into the bloodstream. Some participants will receive the new combination with sacituzumab tirumotecan, while others will receive standard chemotherapy which may include doxorubicin, epirubicin, or cyclophosphamide. All participants will also receive dexamethasone to help manage side effects, and some may receive capecitabine as part of their treatment.

The main purpose of this research is to determine whether the new treatment combination is more effective at eliminating cancer cells before surgery compared to standard chemotherapy. The study will also track how long participants remain free of cancer after treatment and monitor their overall survival. Researchers will carefully watch for any side effects and evaluate how the treatments affect participants’ quality of life.

The medication Nucresiran is given as an injection using a pre-filled syringe. The study aims to evaluate how well this new treatment works in patients who have heart problems related to protein buildup in their heart tissue. Some participants will receive the study medication, while others will receive a placebo.

During the study, doctors will monitor patients’ heart health and track any heart-related hospitalizations or urgent care visits. The study will also look at how the treatment affects patients’ quality of life and overall survival. Patients may continue taking their regular heart failure medications and other approved treatments for their condition while participating in the study.

The purpose of this research is to determine if mezagitamab can reduce the amount of protein in the urine of people with Primary IgA Nephropathy. During the study, participants will receive either mezagitamab or placebo injections for up to 104 weeks (2 years). The medication or placebo will be given alongside their usual kidney disease treatments.

The study will monitor changes in kidney function and the amount of protein in participants’ urine throughout the treatment period. Researchers will also check for signs of improvement in other symptoms related to kidney disease, including the presence of blood in the urine. The study will track how well participants’ bodies respond to the treatment and measure the amount of medication in their blood.

The medication GSK5764227 is administered through intravenous infusion, which means it is given directly into a vein. The drug comes in the form of a powder that is converted into a solution before being administered. The main purpose of this research is to determine how well this new treatment works and how safe it is for patients who have already received previous treatments for their gastrointestinal cancer.

This is a combined Phase 1b/2 study, which means it will assess both the safety and effectiveness of the treatment. The study is “open-label,” which means all participants will know which treatment they are receiving. Some participants will receive different doses of the medication to help determine which amount works best while maintaining safety. The study will include multiple medical centers to ensure a thorough evaluation of the treatment.

The purpose of this research is to evaluate how well datopotamab deruxtecan works when combined with platinum-based therapy (carboplatin or cisplatin) compared to the standard treatment of gemcitabine with platinum-based therapy. The study is designed for patients whose cancer has progressed during or after previous treatment with enfortumab vedotin and pembrolizumab.

During the study, participants will receive their assigned treatment through intravenous infusion. The medications will be given in cycles, with treatment continuing for up to 120 weeks for datopotamab deruxtecan and up to 5 weeks for the other medications. Throughout the study, doctors will monitor the participants’ response to treatment through various medical examinations and imaging tests.

The purpose of the study is to evaluate how effective and safe CAL101 is for patients with IPF. Participants in the study will receive either CAL101 or a placebo, which is a substance with no active medication. The study will last for about 28 weeks, during which the lung function of participants will be closely monitored to see if there are any improvements. The main focus will be on changes in the amount of air the lungs can hold, known as forced vital capacity (FVC).

Throughout the study, participants will be observed for any side effects or adverse events. The study will also track how many participants experience these events over a period of 40 weeks. This research is important to understand if CAL101 can be a beneficial treatment option for those living with IPF.

The purpose of the study is to see if ferric derisomaltose can help reduce the number of deaths related to heart problems and the number of times patients need to be hospitalized due to worsening heart failure. Participants in the study will be randomly assigned to receive either the iron treatment or no iron treatment. The study will monitor participants over a period of time to track their health outcomes, such as hospital visits and overall survival.

Throughout the study, researchers will collect information on various health indicators, including changes in heart failure symptoms and iron levels in the blood. The study aims to provide valuable insights into whether treating iron deficiency with ferric derisomaltose can improve the health and quality of life for people with Chronic Heart Failure.

The purpose of the study is to see if Ifinatamab deruxtecan can help people with advanced or metastatic ESCC live longer compared to the other chemotherapy treatments. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of up to 54 weeks, during which participants will be closely monitored by healthcare professionals. The study will also look at how the treatment affects the quality of life and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and imaging tests like computed tomography (CT) or magnetic resonance imaging (MRI) to track the progress of the disease. The study aims to provide valuable information on the effectiveness and safety of Ifinatamab deruxtecan for treating ESCC, potentially offering a new option for patients with this challenging condition.

The purpose of the study is to understand how the body absorbs and processes Midazolam when given by these two different methods. This will help determine which method might be more effective or comfortable for patients. The study will involve adult men and women who are terminally ill and have a life expectancy of less than one month. Participants will receive either the subcutaneous or intravenous form of Midazolam to help manage their symptoms.

Throughout the study, researchers will monitor how the medication is absorbed in the body and any changes in symptoms or side effects. This includes checking for any discomfort at the injection site and changes in breathing or oxygen levels. The study aims to provide valuable information that could improve symptom management for terminally ill patients in the future.

The purpose of the study is to see if children with a chronic wet cough improve more when they take Augmentin for 14 days compared to those who take a placebo. Additionally, the study will explore whether extending the treatment to 28 days affects the time it takes for the cough to return. The study will also look at how the bacteria in the airways and gut, as well as inflammation and genetics, might influence the cough and its treatment.

Participants in the study will receive either the medication or the placebo for a set period. Researchers will monitor the children’s symptoms and any changes in their cough. The study will also examine the presence of bacteria and viruses, the diversity of bacteria in the airways and gut, and markers of inflammation in the body. The goal is to understand how these factors relate to the cough and its treatment, and to assess the overall quality of life for the children involved.

Participants in the study will receive one dose of the nasal spray, and the main focus will be on observing any changes in their ability to perform physical activities. The study will measure the distance participants can walk and use a scale called the Borg scale to evaluate their level of exertion or breathlessness during physical activity. The study aims to provide insights into whether this nasal spray can help improve the physical capabilities of those with COPD.

The trial is designed to include both males and females aged between 18 and 64 years who have been diagnosed with COPD according to standard criteria. The study will take place over a period of time, with the goal of understanding the potential benefits of using oxymetazoline nasal spray for improving the quality of life for individuals with COPD.

The purpose of the study is to see which treatment is more effective in helping patients live longer and in slowing down the progression of the cancer as seen on scans. Participants in the study will receive either Ifinatamab Deruxtecan or Docetaxel. The study will monitor how long patients live and how long it takes for the cancer to get worse. The study will also look at other factors, such as how long it takes before patients need another treatment, how the cancer responds to the treatment, and any side effects experienced by the participants.

Participants will be closely monitored throughout the study, which will include regular check-ups and scans to assess the progress of the cancer. The study aims to provide valuable information on the effectiveness and safety of Ifinatamab Deruxtecan compared to Docetaxel in treating metastatic castration-resistant prostate cancer.

The purpose of the study is to evaluate how well participants tolerate the medication over an extended period. Participants who have already shown a response to the treatment in previous trials will continue to take zasocitinib in capsule form. The study will last for up to 108 weeks, during which time participants will be monitored for any side effects or changes in their health. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual drug.

Throughout the study, participants will have regular check-ups to assess their health, including monitoring vital signs and conducting laboratory tests. The study aims to gather information on the long-term effects of zasocitinib to better understand its safety and effectiveness in treating Ulcerative Colitis and Crohn’s Disease.

Participants in the study will undergo a biopsy, which is a procedure to remove a small sample of tissue for testing. The study aims to see how well the µCAN test can provide accurate and reliable information to guide treatment decisions. The test results will help doctors choose the most suitable therapy for patients who have not responded to previous treatments. The study will also monitor the safety of the test and any side effects that may occur during the process.

The trial will take place over several years, with the goal of collecting data on how effective the µCAN test is in providing treatment guidance. Participants will be observed for any adverse events related to the test or study procedures, and their experiences with the test will be recorded through a questionnaire. The study will help improve understanding of how to better treat metastatic colorectal cancer using advanced diagnostic tools.

Participants in the study will be randomly assigned to receive either ILB or Riluzole, and some may receive a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are not biased. The study will last for a period of 48 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. These check-ups will include various tests and assessments to track changes in the participants’ condition.

The study aims to gather information on the safety and effectiveness of ILB, as well as its impact on certain biological markers related to ALS. By comparing the results from the ILB group with those from the Riluzole group, researchers hope to determine if ILB can offer a new and effective treatment option for people living with ALS. The study will also collect data on any side effects experienced by participants to ensure the safety of the treatments being tested.

The purpose of the study is to evaluate the safety of BI 456906 in terms of heart health compared to a placebo. Participants will receive either the treatment or a placebo and will be monitored over time to see if there are any differences in the occurrence of heart-related events such as heart attacks, strokes, or heart failure. The study will also look at changes in body weight, blood pressure, and other health markers over a period of time.

Participants in the study will be followed for several weeks, with regular check-ups to monitor their health and any changes that occur. The study aims to provide valuable information on whether BI 456906 is a safe and effective treatment option for people with obesity and related health conditions. The results could help improve the management of obesity and its complications in the future.

The purpose of the study is to evaluate the effectiveness and safety of nerandomilast over a period of 26 weeks. Participants in the study will receive either the active medication, nerandomilast, or a placebo, which looks like the medication but does not contain the active ingredient. The study will monitor changes in lung health using a special type of imaging called high-resolution computed tomography (HRCT), which provides detailed pictures of the lungs. The study will also track any side effects and changes in symptoms such as cough and shortness of breath.

Participants will be involved in the study for about six months, during which they will have regular check-ups and assessments to monitor their lung condition and overall health. The study aims to provide valuable information on whether nerandomilast can improve lung function and quality of life for people with SARD-ILD. This research could lead to new treatment options for those affected by these challenging conditions.

The purpose of the study is to compare the effectiveness of these treatments in patients who have not received prior treatment for their CLL or SLL. The study will look at how long patients live without their disease getting worse, which is known as progression-free survival. The trial will also explore how the treatment duration can be adjusted based on the measurement of individual residual disease, which refers to the small number of cancer cells that might remain after treatment.

Participants in the study will receive one of the treatment combinations for a set number of cycles. The study will monitor various outcomes, including the overall response to the treatment, the duration of the response, and the time until the next treatment is needed. Safety will also be closely monitored by tracking any adverse events. The study aims to improve treatment outcomes by tailoring the duration of therapy to each patient’s needs.